Franco Pierfrancesco, Potenza Ilenia, Moretto Francesco, Segantin Mattia, Grosso Mario, Lombardo Antonello, Taricco Daniela, Vallario Patrizia, Filippi Andrea Riccardo, Rampino Monica, Ricardi Umberto
Department of Oncology, Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126, Turin, Italy.
Radiotherapy Department, AOU Città della Salute e della Scienza, Turin, Italy.
Radiat Oncol. 2014 Dec 29;9:297. doi: 10.1186/s13014-014-0297-0.
Radiation dermatitis is common in patients treated with combined radiotherapy and chemotherapy for head and neck malignancies. Its timely and adequate management is of uttermost importance for both oncological outcomes and global quality of life. We prospectively evaluated the role of hypericum perforatum and neem oil (Holoil®; RIMOS srl, Mirandola, Italy) in the treatment of acute skin toxicity for patients undergoing radiotherapy or chemo-radiotherapy for head and neck cancer.
A consecutive series of 28 head and neck cancer patients submitted to radiotherapy (RT) was enrolled onto this mono-institutional single-arm prospective observational study. Patients undergoing both definitive or post-operative radiotherapy were allowed, either as exclusive modality or combined with (concomitant or induction) chemotherapy. We started Holoil treatment whenever bright erythema, moderate oedema or patchy moist desquamation were observed. Holoil® was used during all RT course and during follow up time, until acute skin toxicity recovery.
The maximum detected acute skin toxicity was Grade 1 in 7% of patients, Grade 2 in 68%, Grade 3 in 25%, while at the end of RT was Grade 0 in 3.5%, Grade 1 in 32%, Grade 2 in 61%, Grade 3 in 3.5%. For patients having G2 acute skin toxicity, it mainly started at weeks 4-5; for those having G3, it began during weeks 5-6. Median times spent with G2 or G3 toxicity were 17.5 and 11 days. Patients having G2 acute skin toxicity had a dermatitis worsening in 27% of case (median occurrence time: 7 days). G3 events were reconverted to a G2 profile in all patients (median time: 7 days). Those experiencing a G2 skin event were converted to a G1 score in 23% of cases (median time: 14 days). Time between maximum acute skin toxicity and complete skin recovery after RT was 27 days.
Holoil® proved to be a safe and active option in the management of acute skin toxicity in head and neck cancer patients submitted to RT or chemo-radiotherapy. A prophylactic effect in the prevention of moist desquamation may be hypothesized for hypericum and neem oil and need to be tested within a prospective controlled study.
放射性皮炎在接受头颈部恶性肿瘤放化疗联合治疗的患者中很常见。其及时且充分的管理对于肿瘤治疗效果和整体生活质量至关重要。我们前瞻性地评估了贯叶连翘和印楝油(Holoil®;意大利米兰多拉的RIMOS srl公司)在接受头颈部癌放疗或放化疗患者急性皮肤毒性治疗中的作用。
连续纳入28名头颈部癌放疗患者,进行这项单机构单臂前瞻性观察研究。接受根治性放疗或术后放疗的患者均可入组,放疗可作为唯一治疗方式,也可与(同步或诱导)化疗联合使用。一旦观察到明显红斑、中度水肿或斑片状湿性脱皮,即开始使用Holoil治疗。在整个放疗疗程及随访期间均使用Holoil®,直至急性皮肤毒性恢复。
检测到的最大急性皮肤毒性,7%的患者为1级,68%为2级,25%为3级;放疗结束时,0级占3.5%,1级占32%,2级占61%,3级占3.5%。对于2级急性皮肤毒性患者,主要在第4 - 5周开始出现;对于3级患者,在第5 - 6周开始出现。2级或3级毒性持续的中位时间分别为17.5天和11天。2级急性皮肤毒性患者中有27%的病例皮炎加重(中位发生时间:7天)。所有3级事件均在所有患者中转变为2级(中位时间:7天)。经历2级皮肤事件的患者中有23%转变为1级(中位时间:14天)。放疗后最大急性皮肤毒性至皮肤完全恢复的时间为27天。
对于接受放疗或放化疗的头颈部癌患者,Holoil®被证明是一种安全且有效的急性皮肤毒性管理选择。可以推测贯叶连翘和印楝油在预防湿性脱皮方面有预防作用,需要在前瞻性对照研究中进行验证。